Logo Volv Global
Contact

X-Linked Hypophosphataemia

XLH is a hereditary phosphate-wasting disorder causing rickets in children and osteomalacia in adults; most adults were never genetically confirmed and remain difficult to find in claims data.
GET IN TOUCH
LEARN MORE
About X-Linked Hypophosphataemia

In numbers

  • XLH affects approximately 1 in 20,000 people worldwide, with global prevalence estimated at 1.4 to 4.8 per 100,000.
  • UK CPRD data show recorded prevalence rising from 3.1 per million in 1995 to 14.0 per million by 2016, a near five-fold increase attributed to better ascertainment rather than true incidence change.
  • NICE TA993 committee estimates around 1,000 adults with XLH in England, against only 300 currently registered, a detection gap of roughly 700 adults.

Special details

  • XLH follows X-linked dominant inheritance: affected fathers pass the condition to all daughters and no sons, while affected mothers pass it to half their children regardless of sex.
  • Around 70 to 80 percent of cases are familial, with the remaining 20 to 30 percent arising from de novo mutations and no family history.
  • Prevalence is roughly equal between males and females, though heterozygous female carriers often present with a milder phenotype and may remain undiagnosed into adulthood.
Signs and symptoms of X-Linked Hypophosphataemia
Mean diagnostic delay in adults is 3.1 years, with a long tail exceeding 20 years in some cases; sporadic paediatric cases without family history are recognised later, at 2.7 to 4.1 years on average.
Talk to our team
Osteomalacia

Osteomalacia

Bone pain and tenderness, often the dominant complaint in undiagnosed adults.

Pseudofractures

Pseudofractures

Looser zones in weight-bearing bones, sometimes mistaken for stress fractures.

Enthesopathy

Enthesopathy

Progressive calcification of tendons and ligaments causing stiffness and reduced mobility.

Dental abscesses

Dental abscesses

Recurrent and spontaneous, linked to defective dentine mineralisation from childhood.

Lower-limb bowing

Lower-limb bowing

Genu varum or valgum, typically apparent from age one to two years in children.

Key challenges from product development to launch

Strategy and Business

Strategy and Business

  • The wrong disease or indication selected for investment
  • Indications tackled in the wrong order due to shaky success estimates
  • R&D returns slipping below the cost of capital
Clinical Development

Clinical Development

  • Trials delayed by low patient recruitment
  • High screen-failure rates that raise trial cost
  • Mixed cohorts that make the signals difficult to detect
HEOR, Access & Value

HEOR, Access & Value

  • A value case that arrives too late or is underdeveloped
  • Eligible population under-counted, budget-impact case unsubstantiated
  • Approved by the regulator, delayed at HTA
Medical Affairs

Medical Affairs

  • Fragmented, differently-coded healthcare data
  • Diagnostic delay that is long and unequal
  • No shared evidence base across functions
Launch and Commercial

Launch and Commercial

  • Launch planned without a view of the number of findable patients
  • Targeting too broad a population slows early uptake
  • RWE started too late to build the case

How Volv Global Helps

The earliest pipeline decisions carry lasting consequences: the wrong indication chosen, indications pursued in the wrong order, or capital committed where expected returns already trail its cost. Mistakes made this early are expensive to correct later.

inTrigue

Finds the true reachable population per candidate, so indication choices rest on evidence.

volv.global/finding-patients

inFlow

Adds probability-of-success and outcome evidence to help prioritise the pipeline.

volv.global/predict-patient-outcomes

When patients cannot be found, recruitment stalls and the burn rate climbs. High screen-failure rates add further cost and delay, and a mixed cohort makes the results harder to interpret.

inTrigue

Finds the undiagnosed and mis-coded patients conventional feasibility misses, widening the recruitable pool.

volv.global/finding-patients

inCare

Surfaces diagnosed-but-hidden, trial-eligible patients already in the data, so sites enrol faster.

volv.global/stratifying-patient-cohorts

inFlow

Predicts who will progress or respond, enriching the cohort so the signal is not diluted.

volv.global/predict-patient-outcomes

Without strong, timely evidence, payers can restrict access or cut the price. An under-characterised population weakens the budget case, and HTA approval demands more evidence than regulatory approval alone.

inFlow

Generates the real-world evidence and outcomes payers ask for, ahead of the submission deadline.

volv.global/predict-patient-outcomes

inTrigue

Finds the undiagnosed patients missing from the count, so the eligible population holds up under scrutiny.

volv.global/finding-patients

inCare

Surfaces the diagnosed-but-eligible patients who expand the eligible population count.

volv.global/stratifying-patient-cohorts

Healthcare data is fragmented across markets, so evidence has to be rebuilt market by market, slowing decisions. Time to an accurate diagnosis varies by who the patient is and where they are treated.

inTrigue

Works across fragmented, differently-coded data by design, so insight holds up country to country without a rebuild.

volv.global/finding-patients

inAdvance

Detects patients ahead of typical diagnosis, closing the gap in awareness and pathway that drives unequal delay.

volv.global/earlier-detection

A launch planned without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and real-world evidence gathered too late leaves little time to build a strong access dossier.

inTrigue

Finds the treatable patients, so the launch is planned against real demand.

volv.global/finding-patients

inCare

Adds the eligible, reachable patients that launch planning is missing.

volv.global/stratifying-patient-cohorts

inFlow

Builds the access evidence early enough to matter.

volv.global/predict-patient-outcomes

Case Studies about Musculoskeletal diseases

No posts found.

Insights

Logo Volv Global

Your challenge

Our technology

Our solutions

Knowledge Hub

Meet Volv Global

Proprietary Machine Learning Methodology